Role of extracorporeal photopheresis in the management of children with graft‐vs‐host disease

Introduction Graft‐vs‐host disease (GVHD) is a frequent cause of morbidity and mortality in allogeneic stem cell transplants. Extracorporeal photopheresis (ECP) is one of the most accepted second‐line treatments, but technical issues of ECP in children might be prohibitive. Materials and Methods Pat...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical apheresis 2022-12, Vol.37 (6), p.573-583
Main Authors: Asensi Cantó, Pedro, Sanz Caballer, Jaime, Fuentes Socorro, Carolina, Solves Alcaína, Pilar, Lloret Madrid, Pilar, Solís Ruíz, Jürgen, Torres Guerola, Bárbara, Rubia Comos, Javier, Fernández Navarro, José María, Gómez‐Seguí, Ines
Format: Article
Language:English
Subjects:
Apheresis
children
extracorporeal photopheresis
graft‐versus‐host disease
Multivariate analysis
Photodynamic therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Graft‐vs‐host disease (GVHD) is a frequent cause of morbidity and mortality in allogeneic stem cell transplants. Extracorporeal photopheresis (ECP) is one of the most accepted second‐line treatments, but technical issues of ECP in children might be prohibitive. Materials and Methods Patients under 18 y of age with corticodependant or corticorefractory GVHD receiving ECP at our hospital were included in this retrospective study. ECP was performed with an in‐line system (CellExTherakos) in 2013‐2014 and with an off‐line system (Spectra Optia) from 2015 onwards. Cumulative incidence curves were obtained to compare ECP efficacy among patients grouped by different baseline, apheresis, and disease characteristics. Significant variables on univariate analysis (Gray's test) were pooled into a multivariate analysis (Fine‐Gray proportional hazard regression for competing events). Results A total of 701 ECP sessions were performed on 33 patients between October 2013 and December 2021. In total, 97% of the sessions could be executed. In 8% of the sessions an incident was detected, most of them mild and related to catheter dysfunction. With a median follow‐up for alive patients of 33.6 mo (range, 8‐95), the composite partial and complete response cumulative incidence was 70% (95% confidence interval, 51%‐82%) and the median time to maximal response was 2.8 mo (range, 0.25‐9.8). Significantly lower response ratios were found in patients with hepatic, gastrointestinal, acute, or severe GVHD. The only variable that influenced response on multivariate analysis was GVHD severity. Discussion ECP is feasible, safe, and effective for pediatric patients with corticorefractory or corticodependant GVHD, offering a less toxic and nonimmunosuppressive treatment option.
ISSN:0733-2459
1098-1101
DOI:10.1002/jca.22012